LOS ANGELES, July 23, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that it plans to report financial results for the second
quarter 2015 on Thursday, August 6,
2015. The Company also plans to hold a conference call and
webcast on that day at 5:00 pm ET to
discuss the second quarter 2015 financial results and provide a
business update. The call will be hosted by Andrew Gengos, President and CEO.
LIVE CALL:
|
(877) 853-5636
(toll-free); international dial-in: (631) 291-4544; conference code
79781010.
|
WEBCAST:
|
Interested parties
who wish to listen to the webcast should visit the Investor
Relations section of ImmunoCellular's website at www.imuc.com,
under the Events and Presentations tab. A replay of the webcast
will be available one hour after the conclusion of the
event.
|
The conference call will contain forward-looking statements. The
information provided on the teleconference is accurate only at the
time of the conference call, and ImmunoCellular will take no
responsibility for providing updated information except as required
by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a Phase 2 trial of its
lead product candidate, ICT-107, a dendritic cell (DC)-based
immunotherapy targeting multiple stem cell-associated antigens for
newly diagnosed glioblastoma patients. ImmunoCellular's pipeline
also includes: ICT-121, a DC immunotherapy targeting the CD133 stem
cell-antigen in recurrent glioblastoma; ICT-140, a DC immunotherapy
targeting stem cell-associated antigens for ovarian cancer; and the
Stem-to-T cell research program which engineers the patient's
hematopoietic stem cells to generate antigen-specific
cancer-killing T cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-report-second-quarter-2015-financial-results-on-august-6-2015-300118043.html
SOURCE ImmunoCellular Therapeutics, Ltd.